CoChat

Atypical Antipsychotics and Pituitary Tumors: A Pharmacovigilance Study

Szarfman, Ana, Tonning, Joseph M., Levine, Jonathan G., Doraiswamy, P. Murali · 2006 · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Cited by 145

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Study Objective. To analyze the disproportionality of reporting of hyperprolactinemia, galactorrhea, and pituitary tumors with seven widely used antipsychotic drugs. Design. Retrospective pharmacovigilance study. Data Source. United States Food and Drug Administration's Adverse Event Reporting System (AERS) database. Intervention. We initially identified higher‐than‐expected postmarketing reports of pituitary tumors associated with risperidone, a potent dopamine D 2‐receptor antagonist antipsychotic, by analyzing reporting patterns of these tumors in the AERS database. To further examine this association, we analyzed disproportionate reporting patterns of pituitary tumor reports for seven antipsychotics with different affinities for blocking D 2 receptors: aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone, and haloperidol. Measurements and Main Results. To conduct both of these analyses, we used the Multi‐item Gamma Poisson Shrinker (MGPS) data mining algorithm applied to the AERS database. The MGPS uses a Bayesian model to calculate adjusted observed:expected ratios of drug–adverse event associations (Empiric Bayes Geometric Mean [EBGM] values) in huge drug safety databases. The higher the adjusted reporting ratio, or EBGM value, the greater the strength of the association between a drug and an adverse event. Risperidone had the highest adjusted reporting ratios for hyperprolactinemia (EBGM 34.9, 90% confidence interval [CI] 32.8–37.1]), galactorrhea (EBGM 19.9, 90% CI 18.6–21.4), and pituitary tumor (EBGM 18.7, 90% CI 14.9–23.3) among the seven antipsychotics, and one of the highest scores for all drugs in the AERS database. Some tumors were associated with visual field defects, hemorrhage, convulsions, surgery, and severe (> 10‐fold) prolactin elevations. The EBGM values for risperidone for these adverse events were higher in women, but high EBGM values for these events were also seen in men and children. Moreover, the rank order of the EBGM values for pituitary tumors corresponded to the affinities of these seven drugs for D 2 receptors. Conclusion. Treatment with potent D 2‐receptor antagonists, such as risperidone, may be associated with pituitary tumors. These findings are consistent with animal (mice) studies and raise the need for clinical awareness and longitudinal studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1592/phco.26.6.748

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 145

Metadata

Authors
Szarfman, A., Tonning, J. M., Levine, J. G., & Doraiswamy, P. M.
Venue
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Publisher
Wiley
Published
2006-06
Volume
26
Issue
6
Pages
748-758
ISSN
  • 0277-0008 (ISSN-L)
  • 1875-9114
OpenAlex
W2156455388
Cited by
145
References
5
FWCI
17.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atypical Antipsychotics and Pituitary Tumors: A Pharmacovigilance Study. https://app.cochat.ai/papers/10.1592/phco.26.6.748
The paper
Szarfman, A., Tonning, J. M., Levine, J. G., & Doraiswamy, P. M. (2006). Atypical Antipsychotics and Pituitary Tumors: A Pharmacovigilance Study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.26.6.748

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.